Clinical Trial

A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

Study acronym: EXTEND-1b
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-10-23; most recent amendment 2026-01-27.
Status change: Not Yet Recruiting → Recruiting 2025-05-21
Trial Details
NCT Number NCT06658535
Lead Sponsor NuvOx LLC
Conditions Mild Respiratory Distress
Enrollment 18 participants
Start Date 2025-03-13
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-28